Program: Oral and Poster Abstracts
Session: 703. Adoptive Immunotherapy: Poster III
We isolated an scFv antibody clone WT#213 that can specifically recognize WT1 p235-243 peptide (CMTWNQMNL) complexed with HLA-A*24:02 molecule by the screening of human antibody scFv phage display library. We have constructed retrovirus that encodes the CAR consists of WT#213 and intracellular signal transduction domains of CD3z and GITR (WT#213 CAR). We confirmed the specific recognition of endogenous WT1-expressing cells by the CAR-T cells with the intracellular cytokine staining and the 51Cr release cytotoxic assay. Utilizing NOG immunodeficient mice, we demonstrated the effectiveness of adoptive cell therapy with WT#213 CAR against the WT1 expressing HLA-A*24:02 positive human leukemia cells.
To evaluate the safety of the WT#213 CAR, we predicted the potential property of WT#213 CAR to cross-react to normal tissues in humans. We conducted alanine scan analysis of WT1p235-243 peptide that was recognized by WT#213 CAR as well as the TCR derived from CTL clone TAK-1 which recognizes same epitope peptide in association with HLA-A*24:02 to define the amino acids that were critically important in the recognition by the WT#213 CAR or TAK-1-derived TCR. After BLAST search, we synthesized the normal protein-derived peptides with potential risk of cross-reactivity, and tested the recognition of these peptides by WT#213 CAR or TAK-1-derived TCR. Although the critical peptides, and therefore the peptides with potential risk, were quite different between the WT#213 CAR and TAK-1-derived TCR, none of these peptides showed the stimulation of WT#213 CAR or TAK-1-derived TCR.
The results here suggest that the immunotherapy with WT#213 CAR will be effective for the treatment of the leukemia patients without the predicted risk at least in the evaluation we performed.
Disclosures: Ikeda: Takara Bio Inc.: Research Funding . Akahori: Takara Bio Inc.: Research Funding . Miyahara: Takara Bio Inc.: Research Funding . Amaishi: Takaa Bio Inc.: Employment . Okamoto: Takara Bio Inc.: Employment . Mineno: Takara Bio Inc.: Employment . Takesako: TAKARA BIO INC.: Employment . Fujiwara: Celgene: Honoraria , Other: Travel, Acomodations, Expenses .
See more of: Adoptive Immunotherapy
See more of: Oral and Poster Abstracts
*signifies non-member of ASH